Mylan Pharma launches chronic hepatitis C drug in India

Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N V, announced on Thursday, the launch of Velpatasvir 100 mg/Sofosbuvir 400 mg tablets under the brand name MyHep All in India.

MyHep All is a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus infection in adults, including all six major HCV genotypes. A Velpatasvir 100 mg /Sofosbuvir 400 mg combination product is currently sold by Gilead Sciences in other markets under the brand name EPCLUSA, according to the company.

HCV is a blood-borne virus commonly transmitted through unsafe injection practices, inadequate sterilisation of medical equipment, and the